European Primary Care Cardiovascular Society

U-Prevent: a new tool to individual effect of medication on CVD

Oct. 16, 2018 - news

The UMC Utrecht's Center for Circulatory Health has developed algorithms with which the risk of CVD and the effect of medication to reduce this risk, can be predicted for every adult. Use of the risk calculators is free.

How quickly T2DM progresses is determined by multiple factors

Oct. 3, 2018 - news

EASD 2018 A study found various clinical and biochemical factors that are associated with a greater risk of fast disease progression in T2DM patients.

Statins only in elderly T2DM patients aged <85 years in primary prevention

Oct. 3, 2018 - Ramos R et al. - BMJ 2018

In a retrospective cohort study, statin treatment was significantly related to a reduction in the incidence of ASCVD and in all-cause mortality in elderly T2DM patients aged <85 years, which reduced after the age of 85 years and disappeared in nonagenarians.

Managing elevated lipids in primary care

Scroll down to download a free copy

EPCCS Consensus Guidance for Primary Care
EPCCS Consensus Guidance for Primary Care

This EPCCS Practical Guidance Document provides a brief scientific background on the need for lipid lowering in individuals at high CV risk, and practical guidance on management of persons with dyslipidaemia in primary care, with a focus on challenges faced in clinical reality.

Substantial variation of time to benefit between cholesterol-lowering agents

Aug. 3, 2018 - Barter PJ, Waters DD. - J Clin Lipidol. 2018

An explorative study compared the timepoint at which outcome curves separate among 17 statin and 7 non-statin trials. Results suggest that futility should not be declared too early in trials.

Effects antihypertensive and lipid-lowering therapy on CV risk not influenced by lifestyle

Aug. 2, 2018 - Dagenais GR, et al. - J Am Heart Assoc. 2018

A post hoc analysis of a randomized trial showed reduced CVD risk after rosuvastatin therapy with and without candestartan/hydrochlorothiazide, regardless of the number of healthy lifestyle factors.

Lipids and food

July 11, 2018 - Prof. David Marais - Cape Town, South Africa
Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in  persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.

Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.

The cardiovascular challenge for primary care in diabetes

July 10, 2018 - Prof. Richard Hobbs - Oxford, UK
Prof. Hobbs stresses  the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.

PCSK9 inhibitor and statins highly effective in people with diabetes with ACS

June 25, 2018 - news

ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels

Lipid lowering: the evidence, the guidelines, the clinical reality

EPCCS CV Summit 2018

Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Professor Frank Visseren, Utrecht, The Netherlands
A recording of the lecture by Prof. Visseren, on practical issues of managing elevated lipids and statins: why do many patients not take their medication, and how can we improve this?

EPCCS 2018 A recording of the lecture by Prof. Visseren, on practical issues of managing elevated lipids and statins: why do many patients not take their medication, and how can we improve this?

Google searches and statin-intolerance

May 16, 2018 - news

A Google-driven nocebo effect may underlie statin intolerance, as countries with many websites on statin side-effects showed a higher prevalence of statin intolerance.

CV benefit of long-term statin treatment far outweighs adverse effects, says EAS Consensus Panel

May 3, 2018 - Mach F et al., Eur Atheroscl Soc Consensus Panel - Eur Heart J, 2018

Based on objective and critical appraisal of the literature on potential adverse effects of statins, the EAS Consensus Panel concludes that statin treatment is remarkably safe.